-
AbCellera, which is developing a treatment for COVID-19, has announced clinical testing for its antibody drug could start as soon as July, CTV News reported.
-
The company has isolated around 500 antibodies that are candidates for new therapeutics to treat or prevent infections.
-
CEO Carl Hansen said the antibodies were identified in a single blood sample from one of the first COVID-19 patients in North America.
-
Last month, Canadian Prime Minster Justin Trudeau said that AbCellera would be among several Canadian companies receiving $192 million in federal funding for vaccine and treatment research.
To read more NewsPoints articles, click here.
